Computational oncology is a generic term that encompasses any form of computer-based
modelling relating to tumour biology and cancer therapy. Mathematical modelling can be …

The importance of polymorphisms in the dihydropyrimidine dehydrogenase (DPD) gene
(DPYD) for the prediction of severe toxicity in 5-fluorouracil (5-FU) based chemotherapy has …

The fluoropyrimidines are the mainstay chemotherapeutic agents for the treatment of many
types of cancers. Detoxifying metabolism of fluoropyrimidines requires dihydropyrimidine …

Purpose: To explore the effect of dihydropyrimidine dehydrogenase (DPD) single nucleotide
polymorphisms (SNP) and haplotypes on outcome of capecitabine. Experimental Design …

Background: Fluoropyrimidine drugs are extensively used for the treatment of solid cancers.
However, adverse drug reactions are a major clinical problem, often necessitating treatment …

Capecitabine is an oral prodrug of 5-fluorouracil (5-FU) and approved for treatment of
various malignancies. Hereditary genetic variants may affect a drug's pharmacokinetics or …

Background Pretherapeutic screening for dihydropyrimidine dehydrogenase (DPD)
deficiency is recommended or required prior to the administration of fluoropyrimidine-based …

The fluoropyrimidine anticancer drugs, especially 5-fluorouracil (5-FU) and capecitabine,
are frequently prescribed for several types of cancer, including breast, colorectal, head and …

In the field of pharmacogenetics, we currently have a few markers to guide physicians as to
the best course of therapy for patients. For the most part, these genetic variants are within a …

Fluoropyrimidine drugs (FP) are the backbone of many chemotherapy protocols for treating
solid tumours. The rate-limiting step of fluoropyrimidine catabolism is dihydropyrimidine …